Therefore, enhancing the secretion and presentation of immunogenic neoantigens, such as through tumor vaccines or cytokine therapies, to activate immune cells, especially CD8+ T cells, may be a promising treatment strategy for HRP tumors. This evidence concerns the gene CD8A and neoplasm.